Sign up Australia
Proactive Investors - Run By Investors For Investors

Genetic Technologies tops ASX Most Traded ahead of Nasdaq trading

Genetic Technologies has traded $1.7 million of stock by noon.
Genetic Technologies tops ASX Most Traded ahead of Nasdaq trading
The ASX most active

Genetic Technologies Ltd (ASX:GTG; Nasdaq:GENE) is the most active stock intra-day with over 113 million shares changing hands, although its value has eased 10.5% to $0.017.

The company has regained compliance with Nasdaq Marketplace following a deficiency notice in mid-2017.

Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health.

The company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

Adding interest and following a strategic review, the company remains in active discussions with multiple parties regarding a potential transaction.

Further details will be closely monitored by investors.

Company Name Code Last Change Volume
Genetic Technologies Ltd GTG $0.017 -10.53% 113,744,014
Pancontinental Oil & Gas NL PCL $0.005 0% 95,747,144
Queensland Bauxite Ltd QBL $0.069 -8% 71,822,947
Bard1 Life Sciences Ltd BD1 $0.016 33.33% 64,333,658
Atlas Iron Ltd AGO $0.032 -3.03% 64,299,962
Ardiden Ltd ADV $0.023 15% 61,450,080
Serpentine Technologies Ltd S3R $0.017 21.43% 49,188,225
Fatfish Internet Group Ltd FFG $0.100 21.95% 36,935,922
Kairos Minerals Ltd KAI $0.055 14.58% 32,602,587
Lepidico Ltd LPD $0.067 6.35% 27,529,056


View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

September 20 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”
Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.
Throne of Glass
April 30 2018
Rowling, Rowling, Rowling ... keep those titles rolling. Mind you, it's not all about Ms Rowling; Sarah J Maas title revenues grew 47% in the first half of the financial year and dieters are gorging on Tom Kerridge's books

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use